Results 151 to 160 of about 58,749 (205)

Population Pharmacokinetics of Polymyxin B

Clinical Pharmacology & Therapeutics, 2018
Polymyxin B is used as a last treatment resort for multidrug‐resistant Gram‐negative bacterial infections. The objectives of this study were to examine the population pharmacokinetics of polymyxin B and investigate factor(s) influencing pharmacokinetic variability.
Pooja, Manchandani, Visanu, Thamlikitkul, Yanina, Dubrovskaya, Jessica T, Babic, David C, Lye, Lawrence S, Lee, Vincent H, Tam   +6 more
openaire   +2 more sources

DANGER OF POLYMYXIN B

Archives of Dermatology, 1963
To the Editor : In the June, 1961, issue of theArchives of Dermatology, G. Asboe-Hansen, M.D., Copenhagen, Denmark, reported the therapeutical essay of polymyxin B (Pfizer) in a case of generalized mastocytosis. We tried this treatment, utilizing disyncran as a cover against histamine liberation, in a case of urticaria pigmentosa which had resisted ...
openaire   +2 more sources

Clinical Use of Polymyxin B

2019
Polymyxin B is another clinically available polymyxin that has re-emerged in clinical practice to treat infections caused by multi-drug (MDR) or extensively-drug-resistant (XDR) Gram-negative bacteria (GNB). Its chemical structure is very similar to the structure of polymyxin E (colistin).
Maria Helena, Rigatto, Diego R, Falci, Alexandre P, Zavascki   +2 more
openaire   +2 more sources

B‐Cell Activating Properties of Polymyxin B

Scandinavian Journal of Immunology, 1978
Polymyxins are known to be inhibitors of certain polyclonal B cell activators such as lipopolysac‐charide and dextransulphate. However, increased specific responses to hapten‐coupled mitogens have been reported after the addition of polymyxins to superoptimal conjugate doses.
C I, Smith, L, Hammarström
openaire   +2 more sources

Polymyxin B and Colistin

New England Journal of Medicine, 1964
GRAM-negative bacilli, in particular pseudomonas species, are of increasing concern to the clinician as infectious and therapeutic problems.1 , 2 Accordingly, polymyxin B has grown to singular importance as its utility to the treatment of systemic infections caused by pseudomonas species has been appreciated and exploited.
N M, NORD, P D, HOEPRICH
openaire   +2 more sources

Polymyxin B: similarities to and differences from colistin (polymyxin E)

Expert Review of Anti-infective Therapy, 2007
Hospital-acquired infections due to multidrug-resistant gram-negative bacteria constitute major health problems, since the medical community is continuously running out of available effective antibiotics and no new agents are in the pipeline. Polymyxins, a group of antibacterials that were discovered during the late 1940s, represent some of the last ...
Andrea, Kwa, Sofia K, Kasiakou, Vincent H, Tam, Matthew E, Falagas   +3 more
openaire   +2 more sources

Prolonged Treatment with Polymyxin B

New England Journal of Medicine, 1960
BECAUSE polymyxin B has significant toxic potentialities its use is sharply circumscribed, and prolonged therapy with it is avoided. This report describes an unusual case in which circumstances necessitated the administration of polymyxin B for almost one year to a patient with a single functioning kidney.
openaire   +2 more sources

Peptide Antibiotics (Polymyxin B and Polymyxin E)

1978
Of the five polymyxins, A, B, C, D and E, originally isolated from a spore-bearing bacillus called variously B. aerosporus and B. polymyxa (Garrod et al., 1973), only two have found clinical usefulness, namely polymyxin B, usually in the form of the sulphate, and polymyxin E (colistin), either as the sulphate or sodium sulphomethate.
A. P. Ball, J. A. Gray, J. McM. Murdoch
openaire   +1 more source